EE9900036A - Novel compounds and compositions for the treatment of diseases associated with tryptase activity - Google Patents
Novel compounds and compositions for the treatment of diseases associated with tryptase activityInfo
- Publication number
- EE9900036A EE9900036A EEP199900036A EE9900036A EE9900036A EE 9900036 A EE9900036 A EE 9900036A EE P199900036 A EEP199900036 A EE P199900036A EE 9900036 A EE9900036 A EE 9900036A EE 9900036 A EE9900036 A EE 9900036A
- Authority
- EE
- Estonia
- Prior art keywords
- compositions
- treatment
- novel compounds
- diseases associated
- tryptase activity
- Prior art date
Links
- 102000001400 Tryptase Human genes 0.000 title 1
- 108060005989 Tryptase Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2313996P | 1996-07-30 | 1996-07-30 | |
| US89577297A | 1997-07-17 | 1997-07-17 | |
| PCT/US1997/013422 WO1998004537A1 (en) | 1996-07-30 | 1997-07-30 | Novel compounds and compositions for treating diseases associated with tryptase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE9900036A true EE9900036A (en) | 1999-08-16 |
Family
ID=26696778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP199900036A EE9900036A (en) | 1996-07-30 | 1997-07-30 | Novel compounds and compositions for the treatment of diseases associated with tryptase activity |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0934293A1 (en) |
| JP (1) | JP2001509787A (en) |
| KR (1) | KR20000029679A (en) |
| CN (1) | CN1073103C (en) |
| AU (1) | AU733621B2 (en) |
| CA (1) | CA2262542A1 (en) |
| CZ (1) | CZ29799A3 (en) |
| EE (1) | EE9900036A (en) |
| FI (1) | FI990171L (en) |
| HU (1) | HUP0003267A3 (en) |
| LV (1) | LV12291B (en) |
| NO (1) | NO990433L (en) |
| NZ (1) | NZ333713A (en) |
| PL (1) | PL331465A1 (en) |
| SI (1) | SI9720047A (en) |
| SK (1) | SK8599A3 (en) |
| WO (1) | WO1998004537A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
| AU2723099A (en) * | 1998-02-06 | 1999-08-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| EP1060175B1 (en) * | 1998-02-06 | 2004-11-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tryptase inhibitors |
| AU5625499A (en) * | 1998-09-04 | 2000-03-27 | Altana Pharma Ag | Novel pyranoses |
| AU777026B2 (en) | 1999-08-10 | 2004-09-30 | Altana Pharma Ag | Novel tryptase inhibitors |
| WO2001019809A1 (en) * | 1999-09-14 | 2001-03-22 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| WO2001036386A1 (en) * | 1999-11-17 | 2001-05-25 | Sumitomo Pharmaceuticals Co., Ltd. | Diabetic remedy containing dipiperazine derivative |
| DE19955476A1 (en) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments |
| JP2003518087A (en) | 1999-12-20 | 2003-06-03 | アルタナ ファルマ アクチエンゲゼルシャフト | Tryptase inhibitor |
| WO2001046168A1 (en) * | 1999-12-20 | 2001-06-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
| EP1358182B1 (en) | 2001-01-31 | 2004-08-11 | ALTANA Pharma AG | Diazocine derivatives and their use as tryptase inhibitors |
| JP2004518736A (en) | 2001-02-21 | 2004-06-24 | アルタナ ファルマ アクチエンゲゼルシャフト | Tryptase inhibitor |
| WO2002066420A2 (en) * | 2001-02-21 | 2002-08-29 | Altana Pharma Ag | Tryptase inhibitors |
| WO2002074732A2 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
| WO2002074733A2 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| HUP0400183A2 (en) | 2001-06-11 | 2004-07-28 | Xenoport Inc. | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
| US7232924B2 (en) | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6962941B2 (en) | 2001-06-19 | 2005-11-08 | Altana Pharma Ag | Tryptase inhibitors |
| NZ554737A (en) | 2004-11-04 | 2011-04-29 | Xenoport Inc | Gabapentin prodrug sustained release oral dosage forms |
| MX2011006353A (en) | 2008-12-19 | 2011-07-13 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases. |
| TWI432188B (en) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases |
| FR3038605B1 (en) | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | VICINAL PRIMARY DIAMINS ASSOCIATED WITH CHELATING MOTIFS OF METALS AND / OR FREE RADICALS, ACTIVE AGAINST CARBONYL AND OXIDIZING STRESSES AND THEIR USE |
| CA3063334A1 (en) * | 2017-05-12 | 2019-12-05 | Riken | Modified class a gpcr binding compound |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845242A (en) * | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
| NZ263084A (en) * | 1993-03-12 | 1997-08-22 | Arris Pharm Corp | Dipeptide derivatives, treatment of immunomediated inflammatory disorders |
| SK282537B6 (en) * | 1993-03-12 | 2002-10-08 | Axys Pharmaceuticals, Inc. | Tryptase inhibitor and its pharmaceutically acceptable salt, phar maceutical preparation containing it and its use |
| JPH10501238A (en) * | 1994-06-01 | 1998-02-03 | アリス ファーマシューティカル コーポレイション | Compositions and methods for treating mast cell mediated conditions |
| MX9702125A (en) * | 1994-09-23 | 1998-04-30 | Arris Pharm Corp | Compositions and methods for treating mast-cell inflammatory condition. |
| CZ298197A3 (en) * | 1995-03-24 | 1998-03-18 | Arris Pharmaceutical Corporation | Reversible inhibitors of proteases |
| TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-07-30 EP EP97937066A patent/EP0934293A1/en not_active Withdrawn
- 1997-07-30 KR KR1019997000757A patent/KR20000029679A/en not_active Withdrawn
- 1997-07-30 NZ NZ333713A patent/NZ333713A/en unknown
- 1997-07-30 CA CA002262542A patent/CA2262542A1/en not_active Abandoned
- 1997-07-30 CN CN97196877A patent/CN1073103C/en not_active Expired - Fee Related
- 1997-07-30 SI SI9720047A patent/SI9720047A/en unknown
- 1997-07-30 SK SK85-99A patent/SK8599A3/en unknown
- 1997-07-30 HU HU0003267A patent/HUP0003267A3/en unknown
- 1997-07-30 AU AU39670/97A patent/AU733621B2/en not_active Ceased
- 1997-07-30 WO PCT/US1997/013422 patent/WO1998004537A1/en not_active Application Discontinuation
- 1997-07-30 EE EEP199900036A patent/EE9900036A/en unknown
- 1997-07-30 PL PL97331465A patent/PL331465A1/en unknown
- 1997-07-30 CZ CZ99297A patent/CZ29799A3/en unknown
- 1997-07-30 JP JP50913698A patent/JP2001509787A/en active Pending
-
1999
- 1999-01-29 FI FI990171A patent/FI990171L/en unknown
- 1999-01-29 NO NO990433A patent/NO990433L/en not_active Application Discontinuation
- 1999-02-18 LV LVP-99-27A patent/LV12291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LV12291A (en) | 1999-06-20 |
| CN1073103C (en) | 2001-10-17 |
| FI990171L (en) | 1999-03-23 |
| WO1998004537A1 (en) | 1998-02-05 |
| CN1226892A (en) | 1999-08-25 |
| NZ333713A (en) | 2000-12-22 |
| EP0934293A1 (en) | 1999-08-11 |
| FI990171A0 (en) | 1999-01-29 |
| CZ29799A3 (en) | 1999-06-16 |
| SK8599A3 (en) | 2000-03-13 |
| HUP0003267A3 (en) | 2002-02-28 |
| CA2262542A1 (en) | 1998-02-05 |
| AU733621B2 (en) | 2001-05-17 |
| LV12291B (en) | 2000-04-20 |
| JP2001509787A (en) | 2001-07-24 |
| NO990433D0 (en) | 1999-01-29 |
| HUP0003267A2 (en) | 2001-06-28 |
| AU3967097A (en) | 1998-02-20 |
| KR20000029679A (en) | 2000-05-25 |
| SI9720047A (en) | 1999-08-31 |
| PL331465A1 (en) | 1999-07-19 |
| NO990433L (en) | 1999-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE9900036A (en) | Novel compounds and compositions for the treatment of diseases associated with tryptase activity | |
| FI953180A0 (en) | Compositions for the treatment of diabetic complications | |
| FI952721L (en) | Substance for the treatment of hepatobiliary diseases | |
| ATE179610T1 (en) | COMPOSITION FOR THE TREATMENT OF OVARIAN ESTROGEN-DEPENDENT DISEASES | |
| DE69117117D1 (en) | Cleaning composition for the prevention and alleviation of skin irritation | |
| NO20006630L (en) | Pharmaceutical composition for the treatment of diabetes | |
| FI971969A0 (en) | Compositions and method of use for the treatment of hemorrhoids | |
| FI963696L (en) | Gel for the treatment of skin diseases and skin disinfection | |
| PT934057E (en) | MEDICAL FORMULATIONS OF AEROSOLS WITH FORMOTEROL | |
| PT900225E (en) | ALKYL-4-SILYL PHENOIS AND ESTERS OF THESE AS ANTI-ACETYCLEROTIC AGENTS | |
| DE69812784D1 (en) | Composition for the prevention and elimination of plant diseases | |
| EE04055B1 (en) | Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity, and their use | |
| FI965204A0 (en) | Medical use of bromelain | |
| DE69620691D1 (en) | Therapeutic agent for the treatment of hypercholesterolemia | |
| DE69405919D1 (en) | Compositions for the treatment of keratin fibers | |
| NO991459L (en) | Use of 1-hydroxy-2-pyridones for the treatment of skin infections | |
| DE69807466D1 (en) | TRIPTOLID DERIVATIVES USEFUL FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| DE69822297D1 (en) | TRIPTOLID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| DE69913380D1 (en) | COMPOSITION FOR THE TREATMENT OF PERIODONTAL DISEASES | |
| HUP0000785A3 (en) | Ointment for the treatment of burns and other skin diseases | |
| NO982562D0 (en) | Composition for the treatment of pain | |
| FI944687L (en) | Composition for the prevention and treatment of myopia | |
| NO963482D0 (en) | Medical application of bromelain | |
| FI952953L (en) | Agents for the treatment of metabolic bone diseases | |
| BR9507732A (en) | Pharmaceutical composition for the treatment of glaucoma |